Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a, Multi-centre, Open-label, Non-randomized Study to Assess the Safety, Biodistribution and Tumour Uptake of [I-124]-CPD-1028 Injection

NCT02134340 is registered in ClinicalTrials.gov with Centre for Probe Development and Commercialization as lead sponsor.

NCT NCT02134340
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02134340 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a, Multi-centre, Open-label, Non-randomized Study to Assess the Safety, Biodistribution and Tumour Uptake of [I-124]-CPD-1028 Injection
Lead sponsor
Centre for Probe Development and Commercialization
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2014
Completion date
June 30, 2016
Enrollment
2 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cancer